## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Review Proposal Project**

### NICE Technology Appraisal No.246; Pharmalgen for the treatment of venom allergy

### Matrix of consultees and commentators

NICE Technology Appraisal No.246; Pharmalgen for the treatment of venom allergy Issue date: July 2017

- Department of Health
- NHS Ealing CCG
- NHS England
- NHS Wandsworth CCG
- Welsh Government

- Sanofi (promethazine)
- Thornton & Ross (chlorphenamine)
- Wockhardt UK (chlorphenamine)

#### Relevant research groups

- Asthma, Allergy & Inflammation Research Charity
- David Hide Asthma and Allergy Research Centre
- MRC Clinical Trials Unit
- National Institute for Health Research

#### Associated Public Health Groups

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

NICE Technology Appraisal No.246; Pharmalgen for the treatment of venom allergy Issue date: July 2017

#### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### **Commentators**

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.